5-acetylfuro<2,3-b>pyridine | 220957-41-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃吡啶类
• 英文名称: 5-acetylfuro<2,3-b>pyridine
• 英文别名: 1-(furo[2,3-b]pyridin-5-yl)ethanone；1-furo[2,3-b]pyridin-5-ylethanone
• CAS: 220957-41-5
• 化学式: C₉H₇NO₂
• 分子量: 161.16
• InChiKey: OUJWJKBMKQBRTR-UHFFFAOYSA-N

物化性质

• 沸点：
  256.5±20.0 °C(Predicted)
• 密度：
  1.229±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  43.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  甲基溴化镁 、 呋喃并[2,3-b]吡啶-5-甲腈 在 硫酸 作用下， 生成 5-acetylfuro<2,3-b>pyridine
  参考文献：
  名称：

  呋喃吡啶。XXV †。5-取代的呋喃[2,3- b ]吡啶的合成

  摘要：

  通过Sandmeyer反应，由5-硝基化合物1制备在环氮的β位具有取代基的呋喃[2,3- b ]吡啶衍生物（2-8）。

  DOI：

  10.1002/jhet.5570350611

文献信息

• CARBINOL DERIVATIVES HAVING CYCLIC LINKER
  申请人：Yamaguchi Yuki

  公开号：US20100048610A1

  公开（公告）日：2010-02-25

  [Object] To provide a novel LXRβ agonist that is useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease. [Solving Means] A carbinol compound represented by the following general formula (I) or salt thereof, or their solvate.

  提供一种新型的LXRβ激动剂，可用作预防和/或治疗动脉粥样硬化；动脉硬化，如糖尿病引起的动脉硬化；血脂异常；高胆固醇血症；与脂质相关的疾病；由炎性细胞因子引起的炎症性疾病；过敏性皮肤病；糖尿病；或阿尔茨海默病的治疗剂。【解决手段】以下一般式（I）所表示的羟甲基化合物或其盐，或其溶剂化合物。
• Thiazole derivatives
  申请人：Nakajima Takao

  公开号：US20070105919A1

  公开（公告）日：2007-05-10

  (Wherein n is an integer of from 0 to 3; R 1 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, a substituted or unsubstituted alicyclic heterocyclic group, or a substituted or unsubstituted aromatic heterocyclic group; R 2 is halogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, a substituted or unsubstituted alicyclic heterocyclic group, a substituted or unsubstituted aromatic heterocyclic group, —COR 8 , or the like; R 3 and R 4 may be the same or different, and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aralkyl, —COR 12 , or the like) For example, provided are adenosine A 2A receptor antagonists comprising, as the active ingredient, a thiazole derivative represented by a general formula (I), or a pharmaceutically acceptable salt thereof, and the like.

  其中n为0至3的整数；R1代表取代或未取代的环烷基、取代或未取代的芳基、取代或未取代的脂环杂环基或取代或未取代的芳香杂环基；R2代表卤素、取代或未取代的低碳基、取代或未取代的芳基、取代或未取代的脂环杂环基、取代或未取代的芳香杂环基、-COR8或类似物；R3和R4可以相同也可以不同，每个代表氢原子、取代或未取代的低碳基、取代或未取代的芳基烷基、-COR12或类似物。例如，提供了包含噻唑衍生物的腺苷A2A受体拮抗剂作为活性成分，其表示为通式（I）或其药学上可接受的盐等。
• THIAZOLE DERIVATIVES
  申请人：Nakajima Takao

  公开号：US20110105486A1

  公开（公告）日：2011-05-05

  Wherein n is an integer of from 0 to 3; R 1A is a 5-membered aromatic heterocyclic group containing at least one oxygen atom; R 2A is —COR 8 (wherein R 8 is aryl); R 3A is hydrogen or lower alkyl; and R 12 represents cycloalkyl, aryl, aralkyl, alicyclic heterocyclic group, aromatic heterocyclic group, alicyclic hetocyclic-alkyl, or aromatic heterocyclic-alkyl, and R 1A , R 2A , R 3A and R 12 are individually optionally substituted.

  其中n是0到3的整数；R1A是一个含有至少一个氧原子的5-成员芳香杂环基团；R2A是-COR8（其中R8是芳香基）；R3A是氢或较低的烷基；而R12代表环烷基，芳香基，芳基烷基，脂环杂环基团，芳香杂环基团，脂环杂环烷基或芳香杂环烷基，R1A，R2A，R3A和R12都可以个别地选择性地被取代。
• THERAPEUTIC AND/OR PREVENTIVE AGENTS FOR A SLEEP DISORDER
  申请人：Uesaka Noriaki

  公开号：US20100152162A1

  公开（公告）日：2010-06-17

  It is intended to provide an agent for treating and/or preventing sleep disorder containing as an active ingredient a thiazole derivative represented by the general formula (I) (in the formula, R 1 represents a five-membered aromatic heterocyclic group containing at least one oxygen atom or the like, R 2 represents halogen or the like, and R 3 represents —NR 10 R 11 (in the formula, R 10 and R 11 are the same or different and represent a hydrogen atom or the like) or the like) or a pharmacologically acceptable salt thereof.

  该发明旨在提供一种治疗和/或预防睡眠障碍的药剂，其活性成分为一种由通式（I）表示的噻唑衍生物（在公式中，R1表示至少含有一个氧原子的五元芳香杂环基团或类似基团，R2表示卤素或类似基团，R3表示-NR10R11（在公式中，R10和R11相同或不同，表示氢原子或类似基团）或类似基团）或其药理学上可接受的盐。
• SUBSTITUTED CARBINOL COMPOUND HAVING CYCLIC LINKER
  申请人：Kowa Company, Ltd.

  公开号：EP2281817A1

  公开（公告）日：2011-02-09

  It is to provide a novel LXRβ agonist that is useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease. It is a carbinol compound represented by the following general formula (I) or salt thereof, or their solvate.

  本发明旨在提供一种新型 LXRβ 激动剂，可作为动脉粥样硬化、动脉硬化（如糖尿病引起的动脉硬化）、血脂异常、高胆固醇血症、血脂相关疾病、由炎性细胞因子引起的炎症性疾病、皮肤病（如过敏性皮肤病）、糖尿病或阿尔茨海默病的预防和/或治疗药物。 它是由以下通式(I)或其盐或它们的溶解物所代表的醇化合物。